Electrochemical nanobiosensor based on reduced graphene oxide and gold nanoparticles for ultrasensitive detection of microRNA-128

Mohammadnejad, Javad; Basirhaghighi, Niki; Yazdian, Fatemeh; Pourmadadi, Mehrab; Shayeh, Javad Shabani; Omidi, Meisam; Mirshafiei, Mojdeh; Rahdar, Abbas; Díez‐Pascual, Ana M.

doi:10.1016/j.intimp.2023.109960

Cited by 16 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through impedance analysis, the interaction between the electrode and the surface can be effectively probed by modulating the current ( Walcarius et al, 2013 ; Naresh and Lee, 2021 ). A recent advancement involves an electrochemical biosensor employing reduced graphene oxide (RGO) and AuNPs to detect miR-128, showcasing sensitivity with a LOD of 0.08761 fM and 0.00956 fM using label-free and labeling approaches, respectively ( Mohammadnejad et al, 2023 ). Kim and Kang (2023) developed an electrochemical biosensor using a graphitic nano-onion/molybdenum disulfide (MoS 2 ) NSs composite for the detection of human papillomavirus (HPV)-16 and HPV-18 which will help in early diagnosis of cervical cancer ( Kim and Kang, 2023 ).…”

Section: Introductionmentioning

confidence: 99%

A concise overview of advancements in ultrasensitive biosensor development

Shahid,

Nazir,

Khan

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Electrochemical biosensing has evolved as a diverse and potent method for detecting and analyzing biological entities ranging from tiny molecules to large macromolecules. Electrochemical biosensors are a desirable option in a variety of industries, including healthcare, environmental monitoring, and food safety, due to significant advancements in sensitivity, selectivity, and portability brought about by the integration of electrochemical techniques with nanomaterials, bio-recognition components, and microfluidics. In this review, we discussed the realm of electrochemical sensors, investigating and contrasting the diverse strategies that have been harnessed to push the boundaries of the limit of detection and achieve miniaturization. Furthermore, we assessed distinct electrochemical sensing methods employed in detection such as potentiometers, amperometers, conductometers, colorimeters, transistors, and electrical impedance spectroscopy to gauge their performance in various contexts. This article offers a panoramic view of strategies aimed at augmenting the limit of detection (LOD) of electrochemical sensors. The role of nanomaterials in shaping the capabilities of these sensors is examined in detail, accompanied by insights into the chemical modifications that enhance their functionality. Furthermore, our work not only offers a comprehensive strategic framework but also delineates the advanced methodologies employed in the development of electrochemical biosensors. This equips researchers with the knowledge required to develop more accurate and efficient detection technologies.

show abstract

Section: Introductionmentioning

confidence: 99%

A concise overview of advancements in ultrasensitive biosensor development

Shahid,

Nazir,

Khan

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia

Wu,

Wang,

Yang

et al. 2024

Small

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a common and catastrophic hematological neoplasm with high mortality rates. Conventional therapies, including chemotherapy, hematopoietic stem cell transplantation (HSCT), immune therapy, and targeted agents, have unsatisfactory outcomes for AML patients due to drug toxicity, off‐target effects, drug resistance, drug side effects, and AML relapse and refractoriness. These intrinsic limitations of current treatments have promoted the development and application of nanomedicine for more effective and safer leukemia therapy. In this review, the classification of nanoparticles applied in AML therapy, including liposomes, polymersomes, micelles, dendrimers, and inorganic nanoparticles, is reviewed. In addition, various strategies for enhancing therapeutic targetability in nanomedicine, including the use of conjugating ligands, biomimetic‐nanotechnology, and bone marrow targeting, which indicates the potential to reverse drug resistance, are discussed. The application of nanomedicine for assisting immunotherapy is also involved. Finally, the advantages and possible challenges of nanomedicine for the transition from the preclinical phase to the clinical phase are discussed.

show abstract